



## DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

<u>Date</u>	<u>Time</u>	<u>Location</u>
July 18, 2023	10:00am – 3:00pm (CT)	Howerton Building, Room 202 615 Howerton Court Jefferson City, MO 65109

### Additional Meeting Details

The meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**. Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2452 782 9088

Meeting password: 52bYS8fMMMM

#### Join from a Video System/Application

Dial [24527829088@stateofmo.webex.com](tel:24527829088)  
Or dial 173.243.2.68 and enter your meeting number.

#### Join from a Mobile Device (attendees only)

[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[\\* Click HERE for Meeting Documents \\*](#)

### **Opening Statements/Updates**

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:25	Minutes Review	Discussion/Approval
10:25 – 10:45	Pharmacy Program/Budget Update	Elizabeth Short

### **Old Business**

10:45 – 11:00	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

### **New Business**

11:00 – 11:15	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. Resource List	
	iv. PDL Agents	
	v. Prior Authorization	

### **Clinical and Fiscal Edit Review**

11:15 – 12:15	<u>Existing Criteria</u>	Josh Moore
	i. Ampyra Clinical Edit	
	ii. Besremi Clinical Edit	
	iii. C5 Complement Inhibitors Clinical Edit	
	iv. CAR-T Cell Therapy Clinical Edit	
	v. Crysvita Clinical Edit	
	vi. Duchenne Muscular Dystrophy (DMD) Clinical Edit	

- vii. Gamifant Clinical Edit
- viii. Iron – Injectable Step Therapy Edit
- ix. Koselugo Clinical Edit
- x. Luxturna Clinical Edit
- xi. Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit
- xii. Reblozyl Clinical Edit
- xiii. TIMs, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit
- xiv. Tolvaptan Clinical Edit
- xv. Vyvgart Clinical Edit
- xvi. Zometa Clinical Edit

New Criteria or Revision of Existing Criteria

- i. Daybue Clinical Edit
- ii. Enjaymo Clinical Edit
- iii. Filspari Clinical Edit
- iv. Givlaari Clinical Edit
- v. Joenja Clinical Edit
- vi. Synagis Clinical Edit
- vii. Tepezza Clinical Edit

**Break**

12:15 – 12:45 Lunch

**Preferred Drug List Edit Review**

12:45 – 2:00 Existing Criteria Josh Moore

- i. Alpha-Glucosidase Inhibitors PDL Edit
- ii. Amylin Analogs PDL Edit
- iii. Biguanides & Combinations PDL Edit
- iv. Cypropyrin-Associated Periodic Syndrome (CAPS) Agents PDL Edit
- v. DPP-IV Inhibitors & Combinations PDL Edit
- vi. Erythropoiesis Stimulating Agents PDL Edit
- vii. GLP-1 Receptor Agonists & Combination Agents PDL Edit
- viii. Insulin, Mixed PDL Edit
- ix. Insulin, Non-Analogs PDL Edit
- x. Insulin, Rapid Acting PDL Edit
- xi. Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral PDL Edit
- xii. Meglitinides PDL Edit
- xiii. Methotrexate Agents PDL Edit
- xiv. Psoriasis Agents, Oral PDL Edit
- xv. Sulfonylureas, Second Generation PDL Edit
- xvi. Thiazolidinediones & Combinations PDL Edit
- xvii. TIMs, IL17 Antibody/IL17 Receptor Antagonists PDL Edit
- xviii. TIMs, IL23 Inhibitors and IL23/IL12 Inhibitors PDL Edit

New Criteria or Revision of Existing Criteria

- i. Atopic Dermatitis Agents, Immunomodulators PDL Edit
- ii. Bleeding Disorders Agents PDL Edit
- iii. Colony Stimulating Factors PDL Edit
- iv. Growth Hormone Agents, Somatropin PDL Edit
- v. Growth Hormone Releasing Factors, Select Agents PDL Edit
- vi. Insulin, Long Acting PDL Edit
- vii. Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral PDL Edit

- viii. Multiple Sclerosis Agents, Injectable PDL Edit
- ix. Multiple Sclerosis Agents, Oral PDL Edit
- x. Psoriasis Agents, Topical PDL Edit
- xi. SGLT Inhibitors & Combination Agents PDL Edit
- xii. Thrombocytopenia Agents PDL Edit
- xiii. TIMs, IL6 Receptor Inhibitors PDL Edit
- xiv. TIMs, Janus Kinase (JAK) Inhibitors PDL Edit
- xv. TIMs, Misc. Allergy & Asthma Related Monoclonal Antibodies PDL Edit
- xvi. TIMs, Select Agents PDL Edit
- xvii. TIMs, TNF Inhibitors PDL Edit
- xviii. Urinary Tract Antispasmodics PDL Edit

### Program Utilization Information – Conduent Update

2:00 – 2:30	Reports	John Crowley
	i. Call Center Statistics	
	ii. Missouri SmartPA POS Transparency Report	
	iii. “Top 25” Drugs by Cost/Claims	

### Other Business/Closing Comments

2:30 – 2:50	Other Business	Josh Moore
-------------	----------------	------------

*Informal comments will be accepted from members of the audience at various points in the agenda.  
Times noted are approximate, agenda may move more quickly.*

#### Next Meeting: October 17, 2023

Meeting location and attendance options subject to change

Howerton Building, Room 202  
615 Howerton Court  
Jefferson City, MO 65109  
*Public attendance may be limited*

Webex

**Motion to Close:** *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*

**Missouri Board of Pharmacy approved for 5 hours (0.5 CEU) of pharmacy continuing education.**

Webinar Attendees: In order to receive continuing education you must enter the webinar with your name as it appears on your Missouri Pharmacist License to earn credit. You must also email your name as it appears on your Missouri Pharmacist License, mailing address and Missouri pharmacist license number to MO HealthNet Pharmacy Scheduler (MHD.PHARMACYSCHEDULER@dss.mo.gov) within 24 hours after the conclusion of the meeting to earn credit with the subject "MHD Drug Prior Authorization Committee 7/18/23 CE Application". Incomplete submissions will not be processed.

In-Person Attendees: In order to receive continuing education you must sign in with your name as it appears on your Missouri Pharmacist License to earn credit. You must also email your name as it appears on your Missouri Pharmacist License, mailing address and Missouri pharmacist license number to MO HealthNet Pharmacy Scheduler (MHD.PHARMACYSCHEDULER@dss.mo.gov) within 24 hours after the conclusion of the meeting to earn credit with the subject "MHD Drug Prior Authorization Committee 7/18/23 CE Application". Incomplete submissions will not be processed.

CE credit is not submitted to the CPE Monitor.

Certificates will be emailed within 30 days of the meeting. You must save your certificates in case of audit by the Missouri Board of Pharmacy.

CE credit is only valid toward Missouri Board of Pharmacy licensure renewal.